SRC inhibitor saracatinib enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

被引：0
|
作者：
Lu, Fei-Teng [1 ]
Luo, Fan [1 ]
Qiu, Miao-Zhen [1 ]
Cao, Jia-Xin [1 ]
Luo, Qiu-Yun [1 ]
Yang, Da-Jun [2 ]
Zhao, Hong-Yun [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ascentage Pharma Suzhou Co Ltd, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6094
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
    Trefny, Marcel P.
    Kaiser, Monika
    Stanczak, Michal A.
    Herzig, Petra
    Savic, Spasenija
    Wiese, Mark
    Lardinois, Didier
    Laeubli, Heinz
    Uhlenbrock, Franziska
    Zippelius, Alfred
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (08) : 1505 - 1517
  • [42] PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
    Marcel P. Trefny
    Monika Kaiser
    Michal A. Stanczak
    Petra Herzig
    Spasenija Savic
    Mark Wiese
    Didier Lardinois
    Heinz Läubli
    Franziska Uhlenbrock
    Alfred Zippelius
    Cancer Immunology, Immunotherapy, 2020, 69 : 1505 - 1517
  • [43] PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
    Yu, Zhuo
    Zhang, Peiqing
    Gu, Weikuan
    Jiang, Xicheng
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (08) : 2941 - 2943
  • [44] Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
    Min Luo
    Fang Wang
    Hong Zhang
    Kenneth K. W. To
    Shaocong Wu
    Zhen Chen
    Shaobo Liang
    Liwu Fu
    Signal Transduction and Targeted Therapy, 5
  • [45] Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
    Luo, Min
    Wang, Fang
    Zhang, Hong
    To, Kenneth K. W.
    Wu, Shaocong
    Chen, Zhen
    Liang, Shaobo
    Fu, Liwu
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [46] Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
    Roussot, Nicolas
    Kaderbhai, Coureche
    Ghiringhelli, Francois
    CANCERS, 2025, 17 (05)
  • [47] Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy
    Zhang, Qi
    Yang, Chenying
    Gao, Xingsu
    Dong, Ju
    Zhong, Caiyun
    PHYTOTHERAPY RESEARCH, 2024, 38 (02) : 776 - 796
  • [48] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [49] PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
    Aaron Goodman
    Sandip P. Patel
    Razelle Kurzrock
    Nature Reviews Clinical Oncology, 2017, 14 : 203 - 220
  • [50] PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
    Fameli, Antonella
    Nardone, Valerio
    Shekarkar Azgomi, Mojtaba
    Bianco, Giovanna
    Gandolfo, Claudia
    Oliva, Bianca Maria
    Monoriti, Marika
    Saladino, Rita Emilena
    Falzea, Antonella
    Romeo, Caterina
    Calandruccio, Natale Daniele
    Azzarello, Domenico
    Giannicola, Rocco
    Pirtoli, Luigi
    Giordano, Antonio
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    Cusi, Maria Grazia
    Mutti, Luciano
    Botta, Cirino
    Correale, Pierpaolo
    FRONTIERS IN ONCOLOGY, 2022, 12
12345